ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study, (AMC Protocol #A01)

ANCHOR Study Halted Due to Therapy’s High Success Rates.

  • Principal Investigator(s): Lori Panther, MD, MPH
  • Study Contact: Lori Panther, MD, MPH, 617-927-6056,
  • Description of Subjects: HIV+ men, women and transgender people >35 years old
  • Location (Domestic vs. International): University of California at San Francisco; Cornell Medical Center; Montefiore Medical Center/Albert Einstein College of Medicine; Laser Surgery Care NYC; Boston Medical Center; Anal Dysplasia Clinic MidWest; Wake Forest Medical Center
  • Enrollment Period: 2015-2018
  • Enrollment Goal: 5,058 participants
  • Key Exclusion and Inclusion Criteria: Inclusion: diagnosis of high grade squamous intraepithelial lesion(s) (HSIL) of the anus, untreated. Exclusion: history of treated anogenital HSIL or cancer.
  • Available Biological Specimens: Blood, serum, or plasma; DNA; Tissues and Stool
  • How to Request AccessKrista Sharma, The EMMES Corporation (the Study's Operations and Data Management Center) at 401 N. Washington Street, Suite 700, Rockville, MD 20850, telephone 301.251.1161
  • Available Data Description: CD4 counts; HIV viral loads; cytology results; biopsy results
  • Optional Additional Comments: This study has started enrolling participants as of beginning of 2015. All requests for biorepository specimens should be made to EMMES, UCSF, or the National Cancer Institute Office of HIV and AIDS and Malignancy (OHAM).